Skip to content

   Pharma Publications

Neuropsychopharmacology
  • Transcription factors Lef1 and Rest stimulate recovery from depressive states
    Published on 2025-10-07
    11 months ago
  • Early-life neural correlates of behavioral inhibition and anxiety risk
    Published on 2025-10-04
    11 months ago
  • In Memoriam Peter Charles Whybrow, M.D., D.P.M., M.B., F.R.C.P
    Published on 2025-10-04
    11 months ago
  • Preclinical efficacy of the muscarinic agonist ML-007 in psychosis models depends on both M1 and M4 receptors
    Published on 2025-10-04
    11 months ago
  • The genetics of cannabis lifetime use
    Published on 2025-10-03
    12 months ago
  • Transdiagnostic prevention in youth mental health, Part I: rationale, shared risk factors
    Published on 2025-10-02
    12 months ago
  • Inflammatory mechanisms contribute to long-term cognitive deficits induced by perinatal asphyxia via interleukin-1
    Published on 2025-10-02
    12 months ago
« Previous 1 … 43 44 45 46 47 … 143 Next »
Journal of Psychopharmacology
  • Psilocybin for major depressive disorder: An updated systematic review and meta-analysis of randomized clinical trials
    Published on 2024-10-31
    2 years ago
  • Into the wild frontier: Mapping the terrain of adverse events in psychedelic-assisted therapies
    Published on 2024-10-30
    2 years ago
  • Co-use of psychedelics with other substances: Findings from the global psychedelic survey
    Published on 2024-10-29
    2 years ago
  • Effects of positive mGlu5 modulation on D2 signaling and nicotine-conditioned place preference: Mechanisms of epigenetic inheritance in a transgenerational model of drug abuse vulnerability in psychosis
    Published on 2024-10-28
    2 years ago
  • Ketamine use in a large global sample: Characteristics, patterns of use and emergency medical treatment
    Published on 2024-10-18
    2 years ago
  • The impact of cannabidiol placebo on amygdala-based neural responses to an acute stressor
    Published on 2024-10-14
    2 years ago
  • Rapid and sustained reduction of treatment-resistant PTSD symptoms after intravenous ketamine in a real-world, psychedelic paradigm
    Published on 2024-10-14
    2 years ago
« Previous 1 … 43 44 45 46 47 … 154 Next »
European Neuropsychopharmacology
  • Ketanserin exhibits dose- and concentration-proportional serotonin 2A receptor occupancy in healthy individuals: Relevance for psychedelic research
    Published on 2024-09-06
    2 years ago
  • The Transdiagnostic Global Impression – Psychopathology scale (TGI-P): Initial development of a novel transdiagnostic tool for assessing, tracking, and visualising psychiatric symptom severity in everyday practice
    Published on 2024-09-06
    2 years ago
  • The gut-microbiome in adult Attention-deficit/hyperactivity disorder – A Meta-analysis
    Published on 2024-09-06
    2 years ago
  • Effects of antipsychotic treatment on cardio-cerebrovascular related mortality in schizophrenia: A subanalysis of a systematic review and meta-analysis with meta-regression of moderators
    Published on 2024-09-06
    2 years ago
  • The role of biomarkers in clinical development of drugs for neuropsychiatric disorders – A pragmatic guide
    Published on 2024-09-06
    2 years ago
  • GLP-1 agonists and risk of suicidal thoughts and behaviours: Confound by indication once again? A narrative review
    Published on 2024-07-28
    2 years ago
  • Treatment or enhancement? The controversial role of medication in personality disorders
    Published on 2024-07-21
    2 years ago
« Previous 1 … 43 44 45 46 47 … 170 Next »

   Pharma Pub